Indications and clinical use:
Victoza® is indicated for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with:
Metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
Metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.
Metformin and a basal insulin, when diet and exercise plus dual therapy with Victoza® and metformin do not achieve adequate glycemic control.
Victoza® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
Not a substitute for insulin. Should not be used in type 1 diabetes.
Victoza® is not indicated for use in pediatric patients.
Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnant or breastfeeding women
Most serious warnings and precautions:
Risk of thyroid C-cell tumours: In both genders of rats and mice, liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.
Other relevant warnings and precautions:
Cardiovascular effects: Increased heart rate, PR interval prolongation, decreased blood pressure
Should not be used for treatment of diabetic ketoacidosis
Should not be administered intravenously or intramuscularly
Hypoglycemia in combination with a sulfonylurea or insulin
Pen for individual use only
Recent myocardial infarction, stroke, and congestive heart failure
Hepatic and renal impairment
Gastrointestinal disease and adverse reactions
Thyroid disease and adverse reactions
Acute gallbladder disease
For more information:
Please consult the product monograph at http://novonordisk.ca/PDF_Files/our_products/Victoza/Victoza_PM_EN.pdf for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this advertisement.
The product monograph is also available by calling us at 1-800-465-4334.